Carmat and CorWave, two French medtechs specialising in cardiovascular disease, have separately revealed new progress in attempts to get their respective devices to market.

Carmat has stated that it is preparing to begin selling its Aeson artificial heart device in Q2 2021. The device is aimed at people currently awaiting heart transplants in major European nations, of whom there are more than 2,000.

The device is a total artificial heart system designed specifically for patients awaiting heart transplant. It is not amenable to medical therapy or left ventricular assist device (LVAD) implantation.

Aeson, which received a CE mark in 2020, is due to go on sale in Germany in Q2 2021. Ultimately, Carmat intends for the device to be used in the destination therapy market.

CorWave, meanwhile, has revealed that it has raised $40 million in a financing round, which will enable it to begin clinical trials for its LVAD. CorWave’s device features a membrane which produces a pulse mimicking the blood flow and pressure of the patient’s heart.

The membrane has been incorporated to prevent complications that have impacted existing LVADs, such as thrombosis, bleeding and strokes, with around 80 per cent of patients experiencing at least one adverse event within two years of implantation.

CorWave CEO Louis de Lillers said: Heart surgeons today will tell you that the devices need to imitate the natural functioning of the heart. That is what both CorWave and Carmat are trying to achieve in different ways by replicating the physiology of the heart.”

Contact us


Tel: +44 (0)1424 777745

Fax: +44 (0)1424 777746



Kirkham Young Ltd.
The Old Court House
North Trade Road
East Sussex
TN33 0EX